Ray Ramirez, MD
Colon & Rectal Surgery · Suffolk, VANPI 1912960352
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,563 of the $1,889 with a category attached, or 82.7%. Medical Device Business Services, Inc. accounts for 82.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $1,663 and has fallen 98.8% since, to $21 in 2025. That places this record below the midpoint for colon & rectal surgery clinicians in VA, where the typical reported total is $1,889.
Across 11 payments — averaging $171.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$2K
- Johnson & Johnson$192
- Takeda Pharmaceuticals U.S.A., Inc.$49
- Daiichi Sankyo Inc.$25
- Novo Nordisk$21
- Merck$17
- plus $23 from 2 others
What the payments were for
- Consulting fees$1,56383%
- Food & beverage$32717%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 1 | $1,563 |
| Johnson & Johnson | 3 | $192 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Novo Nordisk | 1 | $21 |
| Merck | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
| Braintree Laboratories, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,889 in reported general payments places this provider in the 50th percentile of 46 colon & rectal surgery providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine | 11 | $3,568 |
| ErythromycinErythromycin Base | 27 | $1,257 |
| Neomycin Sulfate | 36 | $178 |
| Hydrocortisone | 11 | $101 |
| Tramadol Hcl | 17 | $40 |
| Metoclopramide Hcl | 25 | $17 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in Suffolk
- Carlos Glanville MirandaSuffolk$5K
- Joseph FrenkelSuffolk$299
- Andrew VorenbergRichmond$560K
- Craig RezacArlington$33K
- Kimberly MatzieFairfax$28K
- Rodolfo PigalargaArlington$24K
- Gregory FitzharrisHampton$22K
- Ayana Chase-GreavesFredericksburg$11K
- Linda FarkasChesapeake$11K
- Emily RivetRichmond$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.